...
首页> 外文期刊>pharmacogenetics >Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population
【24h】

Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population

机译:人类 NAT2 基因的 17 种等位基因变异在白人人群中的鉴定和流行研究

获取原文

摘要

The prevalence and distribution of seven point mutations at the coding region of the highly polymorphic NAT2 gene were studied in 1008 chromosomes from healthy Spanish subjects. Most of the genes studied (78.4) had one or more mutations, distributed in seventeen allelic variants of the NAT2 gene. Three alleles were present at high frequencies, namely NAT2*5B (41.6), NAT2*6A (23.6) and NAT2*4 (21.6). The frequencies for the rest of alleles were: NAT2*12A (2.5), NAT2*6B (2.0), NAT2*13 (1.9), NAT2*5A (1.5), NAT2*7B (1.2), NAT2*12C (1.0), NAT2*5C (0.8), NAT2*14C (0.8), NAT2*14A (0.6), NAT2*5D (0.3), NAT2*12B (0.2), and NAT2*14D (0.1). In addition, we identified two new allelic variants with mutations at 191A +341C +803G (0.1) and 282T + 59OA +803G (0.3) which to our knowledge are described here for the first time. No other combination of mutations was identified, including the previously described allelic variants NAT2*14B, NAT2*14E, NAT2*5E and NAT2*7A. The phenotype predictive capacity of simplified PCR tests including analyses for mutations at 341C and 590A, and more sophisticated tests analysing seven mutations revealed that, in the population studied, the analysis of these two mutations is enough to predict as rapid acetylators over 99.5 subjects with two rapid genes, and about 94 subjects with one rapid gene. Given a prevalence of poor acetylators of about 55 subjects, the simplified analysis would predict the phenotype in about 97.5 subjects.
机译:在来自健康西班牙受试者的 1008 条染色体中研究了高度多态性 NAT2 基因编码区 7 点突变的普遍性和分布。大多数研究的基因(78.4%)具有一个或多个突变,分布在NAT2基因的17个等位基因变体中。3个等位基因高频存在,分别是NAT2*5B(41.6%)、NAT2*6A(23.6%)和NAT2*4(21.6%)。其余等位基因的频率为:NAT2*12A (2.5%)、NAT2*6B (2.0%)、NAT2*13 (1.9%)、NAT2*5A (1.5%)、NAT2*7B (1.2%)、NAT2*12C (1.0%)、NAT2*5C (0.8%)、NAT2*14C (0.8%)、NAT2*14A (0.6%)、NAT2*5D (0.3%)、 NAT2*12B (0.2%) 和 NAT2*14D (0.1%)。此外,我们鉴定了两个新的等位基因变异,其突变分别位于 191A +341C +803G (0.1%) 和 282T + 59OA +803G (0.3%),据我们所知,这是首次描述。未发现其他突变组合,包括先前描述的等位基因变异NAT2*14B、NAT2*14E、NAT2*5E和NAT2*7A。简化的PCR测试的表型预测能力,包括对341C和590A突变的分析,以及分析七个突变的更复杂的测试表明,在所研究的人群中,对这两个突变的分析足以预测为快速乙酰化剂超过99.5%;具有两个快速基因的受试者,以及约94%具有一个快速基因的受试者。鉴于不良乙酰化剂的患病率约为 55%,简化分析将预测约 97.5% 受试者的表型。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号